Finance

Beta
Lists
IONS:NASDAQ
Ionis Pharmaceuticals Inc
$81.18
+3.63%
(+2.84) 1D
$81.18
0.00% (0.00)
After hours
Closed: Jun 26, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IONS...
Open
$78.80
High
$82.63
Low
$78.80
Mkt. cap
13.42B
Avg. vol.
1.81M
Volume
3.83M
52-wk high
$86.74
52-wk low
$39.37
EPS
-$2.10
Beta
0.37
Shares outstanding
165.26M
No. of employees
1K
Open
$78.80
High
$82.63
Low
$78.80
Mkt. cap
13.42B
Avg. vol.
1.81M
Volume
3.83M
52-wk high
$86.74
52-wk low
$39.37
EPS
-$2.10
Beta
0.37
Shares outstanding
165.26M
No. of employees
1K
News stories
From sources across the web
Profile
Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015. Wikipedia
About Ionis Pharmaceuticals Inc
CEOBrett P. Monia Ph.D.
Employees1.4K
Founded1989
HeadquartersCarlsbad, California, United States
SectorBiotechnology
Websiteionis.com
Analyst ratings
Based on 19 analysts giving stock ratings to IONS in the past 3 months
Strong buy
Buy
17
Hold
2
Sell
0
12-month forecast
Based on 19 Wall Street analysts offering 12 month price targets for IONS in the last 3 months.
Highest
Current $81.18
$130.00 (+60.14%)
Average
$104.61 (+28.86%)
Lowest
$75.00 (-7.61%)
Analyst
Recommendation
Action
Price target
Projected
Date
Eliana Merle
Barclays
Buy
Maintained
$115.00
+41.7%
06/26/2026
Jessica Fye
J.P. Morgan
Buy
Reiterated
$90.00
+10.9%
06/24/2026
Gary Nachman
Canaccord Genuity
Buy
Maintained
$110.00
+35.5%
06/24/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
$130.00
+60.1%
06/24/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
$100.00
+23.2%
06/25/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$130.00
+60.1%
06/25/2026
Joseph Stringer
Needham
Buy
Maintained
$105.00
+29.3%
06/25/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
$111.00
+36.7%
06/24/2026
Myles Minter
William Blair
Buy
Maintained
-
-
06/24/2026
Salveen Richter
Goldman Sachs
Hold
Maintained
$75.00
-7.6%
06/24/2026
Yaron Werber
TD Cowen
Buy
Reiterated
$108.00
+33%
06/24/2026
Akash Tewari
Jefferies
Buy
Maintained
$113.00
+39.2%
06/15/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$106.00
+30.6%
06/05/2026
Eric Joseph
Citi
Buy
Initiated
$90.00
+10.9%
05/20/2026
Unknown Analyst
Citi
Buy
Initiated
$115.00
+41.7%
05/15/2026
Justin Kim
Oppenheimer
Buy
Reiterated
$110.00
+35.5%
04/30/2026
Paul Matteis
Stifel Nicolaus
Hold
Maintained
$86.00
+5.9%
04/30/2026
Luca Issi
RBC Capital
Buy
Maintained
$100.00
+23.2%
04/29/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
$100.00
+23.2%
04/24/2026
Unknown Analyst
Canaccord Genuity
Buy
Initiated
$110.00
+35.5%
04/20/2026
Unknown Analyst
Raymond James
Buy
Initiated
$104.00
+28.1%
04/10/2026
Tiago Fauth
Raymond James
Buy
Initiated
$104.00
+28.1%
04/10/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
$100.00
+23.2%
04/02/2026
Last report
Apr 29, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.30 / -$0.78
+60.90%beat
Revenue / Est. (USD)
246.09M / 196.01M
+25.55%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
452.05M
156.72M
203.33M
246.09M
Cost of goods sold
221.61M
220.09M
287.60M
213.16M
Cost of revenue
221.61M
220.09M
287.60M
213.16M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
90.62M
96.81M
130.19M
150.36M
Operating expense
90.62M
96.81M
130.19M
150.36M
Total operating expenses
312.23M
316.90M
417.79M
363.52M
Operating income
139.82M
-160.18M
-214.46M
-117.42M
Other non operating income
102.00K
363.00K
57.00K
-456.00K
EBT including unusual items
123.53M
-128.39M
-227.92M
-92.31M
EBT excluding unusual items
141.84M
-158.30M
-212.36M
-114.89M
Income tax expense
-20.00K
213.00K
1.48M
218.00K
Effective tax rate
-0.02%
-0.17%
-0.65%
-0.24%
Other operating expenses
-
-
-
-
Net income
123.55M
-128.61M
-229.39M
-92.53M
Net profit margin
27.33%
-82.06%
-112.82%
-37.60%
Earnings per share
0.85
-0.61
-1.15
-0.30
Interest and investment income
24.69M
23.68M
24.73M
25.48M
Interest expense
-22.76M
-22.16M
-22.69M
-22.50M
Net interest expenses
1.92M
1.52M
2.04M
2.99M
Depreciation and amortization charges
-
-
-
-
EBITDA
142.68M
-157.31M
-210.56M
-113.46M
Gain or loss from assets sale
236.00K
-3.94M
638.00K
40.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of IONS
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer